A population-based comparison of organ transplant recipients in whom cutaneous squamous cell develops versus those in whom basal cell carcinoma develops

Abstract

A population-based comparison of organ transplant recipients in whom cutaneous squamous cell develops versus those in whom basal cell carcinoma develops To the Editor: Basal cell carcinomas (BCC) occur more frequently than cutaneous squamous cell carcinomas (cSCC) with a general population ratio of 2.5:1. 1 There is wide variation in this ratio likely due to differences in demographics, latitude, and immunosuppression. The ratio is reversed following solid organ transplantation. 2 The Irish National Cancer Registry records first cSCC and BCC, providing a robust dataset to explore patient and transplant-related factors unique to the development of cSCC compared to BCC. We matched datasets from national transplant centers with Irish National Cancer Registry data from 1994 to 2014. Eligible participants were divided into 4 groups; ''cSCC only,'' ''BCC only,'' ''cSCC and BCC,'' and ''No cSCC or BCC'' and compared using multinomial logistic regression analysis (Supplemental Appendix 1).

Management of Cutaneous Head and Neck Squamous and Basal Cell Carcinomas for Immunocompromised Patients

“…Not all immunosuppressant medications carry the same risk of NMSC development. mTOR inhibitors (e.g., sirolimus and everolimus) and mycophenolate mofetil (MMF) have a reduced incidence of NMSC compared to calcineurin inhibitors [ 27 , 32 , 33 , 34 ]. In 2016, Coghill et al performed a retrospective case–control study to compare the rate of developing cuSCCs with the use of calcineurin agents or mycophenolic acid agents such as MMF in renal and cardiac transplant patients [ 35 ].…”